This website contains information about products that may not be available in all countries, or may be available under different trademarks, for different indications, or in different dosages. Nothing contained herein should be considered a solicitation, promotion or advertisement for any drug including the ones under development on this web site.
Any information on the products contained herein is not intended to provide medical advice nor should be used as a substitute for the advice provided by your physician or other healthcare provider.
Thank you for visiting the Astellas Pharma Inc. Website.
You will enter external sites beyond here. (This link opens in a new window)
TOKYO, September 18, 2018 - Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., “Astellas” ) today announced that it has launched Dafclir® Tablets 200 mg (generic name: fidaxomicin, “Dafclir®”) for the treatment of infectious enteritis (including pseudomembranous colitis1) (susceptible strains: fidaxomicin susceptible Clostridium difficile (CD)2) in Japan.
Dafclir® is an...
TOKYO, September 14, 2018 –Gene Therapy Research Institution Co., Ltd. (head office: Kawasaki, Kanagawa; President: Katsuhito Asai, “GTRI”) and Astellas Pharma Inc. (TSE: 4503, head office: Tokyo, President and CEO: Kenji Yasukawa, Ph.D., “Astellas”) today announced that they have entered into an option agreement for the exclusive negotiation of rights to global development and commercialization...
NEW YORK and TOKYO, August 22, 2018 –Pfizer Inc. (NYSE: PFE) and Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., “Astellas”) today announced amendments to the protocols for two registrational Phase 3 trials, ARCHES and EMBARK, designed to evaluate the safety and efficacy of XTANDI® (enzalutamide) in men with hormone-sensitive prostate cancer (HSPC). These amendments...
TOKYO and CAMBRIDGE, Mass August 21, 2018 - Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., “Astellas” ) and Ironwood Pharmaceuticals, Inc. (Nasdaq: IRWD , “Ironwood”) today announced that approval has been obtained in Japan for the guanylate cyclase-C receptor agonist “Linzess® Tablets 0.25 mg (generic name: linaclotide)” for the additional indication of chronic...